Literature DB >> 3119773

Anterograde vs. retrograde degeneration of the nucleus basalis medialis in Alzheimer's disease.

R C Pearson1, T P Powell.   

Abstract

The evidence that degeneration in the basal forebrain cholinergic nuclei in Alzheimer's disease is a secondary phenomenon is reviewed. Experimental retrograde degeneration in these nuclei shares some common features with the degeneration actually observed in the disease, and can occur without direct damage to the cholinergic axons within the cortex. The neuroanatomical distribution of the pathological changes typical of Alzheimer's disease in the neocortex suggests a progression of the disease process, from the medial temporal cortex and amygdala out into the parieto-temporal association areas. Neurochemical evidence also points to the early and severe involvement of the amygdala in the disease. The close reciprocal relationship between the amygdala and the basal nucleus may underly the degeneration seen in the basal nucleus in Alzheimer's disease.

Entities:  

Mesh:

Year:  1987        PMID: 3119773

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  3 in total

1.  Coeloglossum viride var. bracteatum extract protects against amyloid toxicity in rat prefrontal cortex neurons.

Authors:  Xiao-Yan Qin; Jia Cui; Yan Zhang
Journal:  Int J Clin Exp Med       Date:  2010-03-20

2.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease.

Authors:  Pamela E Potter; Paula K Rauschkolb; Yoga Pandya; Lucia I Sue; Marwan N Sabbagh; Douglas G Walker; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2011-05-01       Impact factor: 17.088

3.  MRI markers for mild cognitive impairment: comparisons between white matter integrity and gray matter volume measurements.

Authors:  Yu Zhang; Norbert Schuff; Monica Camacho; Linda L Chao; Thomas P Fletcher; Kristine Yaffe; Susan C Woolley; Catherine Madison; Howard J Rosen; Bruce L Miller; Michael W Weiner
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.